Loading…
Supernus Pharmaceuticals, Inc. is projected to rise to $58.04 by 2027, a +20% move from its current price of $48.46. SUPN is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $47.64 | $48.50 | $49.37 | +0.08% |
| Jul 14 | $47.33 | $48.54 | $49.78 | +0.16% |
| Jul 15 | $47.10 | $48.58 | $50.10 | +0.24% |
| Jul 16 | $46.91 | $48.62 | $50.39 | +0.32% |
| Jul 17 | $46.75 | $48.66 | $50.64 | +0.40% |
| Jul 18 | $46.61 | $48.69 | $50.87 | +0.48% |
| Jul 19 | $46.48 | $48.73 | $51.09 | +0.56% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $46.48 | $48.73 | $51.09 | +0.56% |
| Week 2 | $45.84 | $49.01 | $52.40 | +1.13% |
| Week 3 | $45.41 | $49.28 | $53.49 | +1.70% |
| Week 4 | $45.09 | $49.56 | $54.48 | +2.28% |
| Week 5 | $44.84 | $49.84 | $55.40 | +2.85% |
| Week 6 | $44.64 | $50.12 | $56.28 | +3.43% |
| Week 7 | $44.48 | $50.41 | $57.12 | +4.02% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Supernus Pharmaceuticals, Inc. is a biopharmaceutical company that engages in the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. It offers Qelbree, a non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD); GOCOVRI for the treatment of dyskinesia and levodopa/carbidopa in patients with Parkinson's Disease (PD); Oxtellar XR, an extended-release oxcarbazepine product indicated for the monotherapy treatment of partial onset epilepsy seizures; and APOKYN for the acute and intermittent treatment of hypomobility or off episodes in patients with advanced PD.
It also provides Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; XADAGO for the treatment of levodopa/carbidopa in patients with PD experiencing off episodes; and MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and chronic sialorrhea. In addition, the company develops ONAPGO, which received FDA approval, for the treatment of motor fluctuations in adults with advanced PD; SPN-817, a first-in-class selective acetylcholinesterase inhibitor, which is in Phase 2 clinical trial, for the treatment of epilepsy, partial seizures, Dravet syndrome, and Lennox-Gaustaut syndrome; SPN-820, a small molecule in Phase 2 clinical trial for treating resistant depression; and SPN-443, a stimulant in Phase 1 trial for the treatment of ADHD/CNS. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors.
It has a development agreement with Navitor Inc. for the conduct of Phase 2 clinical program of SPN-820. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is based in Rockville, Maryland.
SUPN is a CNS-focused biopharma with a current price of $47.41 and a market cap of $2.75B, ranking 1832. The stock sits at a price level that aligns with a multi-year forecast that shows the average price rising from $47.41 in 2026 to higher levels through 2030 and beyond.
Forecasts project a rising path of average prices, reaching $76.40 by 2030 and continuing to $222.39 by 2040 and $409.47 by 2050, with max forecasts climbing to $104.19 in 2030 and $669.62 by 2050. The implied upside is reflected in rising ROIs, from 0% in 2026 to 61.1% in 2030 and up to 763.7% by 2050. The sentiment is bullish in the longer horizon, suggesting meaningful upside over time.
A major floor 16.2% below — a decisive break under it would weaken the trend.
The nearest floor, 10.1% below — buyers have tended to step in here.
The nearest ceiling, 4.1% above — a clean break opens room to run.
A major ceiling 14.7% above — clearing it would confirm fresh momentum.
Key SUPN support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of SUPN market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $48.57 | Sell | $48.50 | Sell |
| MA 10 | $47.84 | Buy | $47.80 | Buy |
| MA 20 | $46.13 | Buy | $47.03 | Buy |
| MA 50 | $47.18 | Buy | $47.29 | Buy |
| MA 100 | $49.23 | Sell | $47.97 | Buy |
| MA 200 | $49.09 | Sell | $47.02 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 57.41 | Neutral |
| Stoch RSI (14) | 59.00 | Neutral |
| CCI (20) | 90.66 | Neutral |
| Williams %R (14) | -33.22 | Info |
| MACD (12,26,9) | 0.50 | Buy |
| ROC (12) | 8.95 | Buy |
| Bollinger %B (20,2) | 0.80 | Neutral |
| Stochastic %K (14) | 66.78 | Neutral |
| TRIX (15) | 0.03 | Buy |
| Awesome (5,34) | 2.53 | Buy |
| Ultimate (7,14,28) | 63.50 | Neutral |
| Momentum (10) | 3.71 | Buy |
| Aroon Osc (25) | 52.00 | Buy |
| Hull MA (9) | 49.52 | Sell |
| ADX (14) | 18.98 | Neutral |
| ATR (14) | 0.80 | Info |
The 30-day range is $42.92 to $52.37. RSI14 is 60 and the sentiment is BULLISH. The SMA50 is $47.32 and the SMA200 is $48.99, with near-term support at $43.58 and resistance at $49.38. The stock shows an annualized volatility of 30, indicating notable short-term variability around the price level.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $43.58 | $48.46 | $68.53 | 0% | Neutral | |
| $47.54 | $58.04 | $74.10 | +20% | Neutral | |
| $53.18 | $66.16 | $86.74 | +37% | Bullish | |
| $57.59 | $72.75 | $97.41 | +50% | Bullish | |
| $59.25 | $75.85 | $103.40 | +57% | Bullish | |
| $69.59 | $90.18 | $124.87 | +86% | Bullish | |
| $79.96 | $104.79 | $147.17 | +116% | Bullish | |
| $89.15 | $118.06 | $167.95 | +144% | Bullish | |
| $98.53 | $131.79 | $189.72 | +172% | Bullish | |
| $97.65 | $131.85 | $191.92 | +172% | Bullish | |
| $150.69 | $212.19 | $323.68 | +338% | Bullish | |
| $260.40 | $393.26 | $643.03 | +712% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $43.58 | $48.46 | $58.84 | +0.00% |
| August 2026 | $44.15 | $51.69 | $61.83 | +6.67% |
| September 2026 | $44.33 | $52.14 | $62.86 | +0.88% |
| October 2026 | $44.93 | $53.07 | $64.39 | +1.77% |
| November 2026 | $46.53 | $55.15 | $67.28 | +3.92% |
| December 2026 | $47.00 | $55.88 | $68.53 | +1.33% |
Click any year to see its month-by-month SUPN forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Supernus Pharmaceuticals, Inc.'s 2026 outlook centres on $48.46, within a $43.58 to $68.53 range. That marks a 0% change versus current levels. A consolidation phase looks the most probable path here.
By 2027, SUPN could reach as high as $74.10, with a base case around $58.04 and support toward $47.54 — roughly +20% from $48.46. Price action looks broadly range-bound.
Expect SUPN to range from $53.18 to $86.74 through 2028. The $66.16 average target implies a +37% move from current prices. That is up +14% on the projected 2027 average. Buyers look set to stay in control over this stretch.
The SUPN price prediction for 2029 points to an average of $72.75 (low $57.59, high $97.41) — a potential gain of +50% on today's $48.46. Momentum favours further upside here.
In 2030, SUPN is projected to trade between $59.25 and $103.40, averaging $75.85 — a potential gain of +57% from today's $48.46. That is up +4% on the projected 2029 average. Buyers look set to stay in control over this stretch.
Supernus Pharmaceuticals, Inc.'s 2031 outlook centres on $90.18, within a $69.59 to $124.87 range. That is up +19% on the projected 2030 average. That marks a +86% change versus current levels. Momentum favours further upside here.
By 2032, SUPN could reach as high as $147.17, with a base case around $104.79 and support toward $79.96 — roughly +116% from $48.46. Buyers look set to stay in control over this stretch.
Expect SUPN to range from $89.15 to $167.95 through 2033. The $118.06 average target implies a +144% move from current prices. That is up +13% on the projected 2032 average. Momentum favours further upside here.
The SUPN price prediction for 2034 points to an average of $131.79 (low $98.53, high $189.72) — a potential gain of +172% on today's $48.46. Buyers look set to stay in control over this stretch.
In 2035, SUPN is projected to trade between $97.65 and $191.92, averaging $131.85 — a potential gain of +172% from today's $48.46. That is up 0% on the projected 2034 average. Momentum favours further upside here.
Supernus Pharmaceuticals, Inc.'s 2040 outlook centres on $212.19, within a $150.69 to $323.68 range. That is up +61% on the projected 2035 average. That marks a +338% change versus current levels. Buyers look set to stay in control over this stretch.
By 2050, SUPN could reach as high as $643.03, with a base case around $393.26 and support toward $260.40 — roughly +712% from $48.46. Momentum favours further upside here.
Investing $1,000 in SUPN today (≈ 20.635576 SUPN) could be worth
$8,115.21
+$7,115.21 (+712%) by 2050 · US Dollar
Based on the average projected SUPN price of $393.26 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in SUPNwould be worth at today's price.
$1,000 invested in SUPN on Jul 10, 2025 (≈ 30.175016 SUPN) would be worth
$1,462.28
+$462.28 (+46.2%) today · 1.46× · US Dollar
Based on a SUPN entry price of $33.14 vs. today's $48.46.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $48.05 | $1,008.53 | +0.9% |
| 1 month ago | $45.09 | $1,074.74 | +7.5% |
| 3 months ago | $50.68 | $956.2 | -4.4% |
| 6 months ago | $51.36 | $943.54 | -5.6% |
| 1 year ago | $33.14 | $1,462.28 | +46.2% |
| All time (5.0y) ago | $27.84 | $1,740.66 | +74.1% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our SUPN forecast.
Our base-case forecast reaches $97.00 around 2032.
Implied market cap at $97.00: $5.63B
2030 forecast: avg $76.40, min $59.66, max $104.19; roiPct 61.1; sentiment BULLISH.
2040 forecast: avg $222.39, min $157.90, max $339.30; roiPct 369.1; sentiment BULLISH.
2050 forecast: avg $409.47, min $271.08, max $669.62; roiPct 763.7; sentiment BULLISH.
These are estimates of future price paths and are not guarantees. The forecast shows a bullish long-term outlook with substantial potential upside, but actual results will depend on market conditions and other factors.
Tap a question to reveal the answer.
2030 avg $76.40; min $59.66; max $104.19; roiPct 61.1; sentiment BULLISH.
The forecast shows bullish sentiment from 2027 onward with positive ROI figures; 2027 avg $57.40; 2027 roi 21.1%; 2040 roi 369.1%; 2050 roi 763.7%.
2030 max $104.19; 2031 max $127.59; thus the price could exceed $100 in 2030 or 2031.
Current price $47.41; market cap $2.75B.
Thirty-day range is $42.92 to $52.37.
Supernus Pharmaceuticals, Inc. Community Discussion
0Share your Supernus Pharmaceuticals, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.